Visceral leishmaniasis is an infectious disease that occurs only rarely in recipients of solid organ grafts but is associated with an elevated mortality rate despite proper treatment. We report five cases diagnosed in our hospital. All the patients were men aged 30 to 60 years who had undergone kidney transplantation (3 patients), heart transplantation (1), or liver transplantation (1). Three of the patients died, one had multiple recurrences, and one developed post-kala-azar cutaneous leishmaniasis. We review the clinical features, treatments, and outcomes of 26 previously reported cases, pointing out the lower cure rate associated with human immunodeficiency virus infection.
Infection is frequently a cause of morbidity and mortality in solid organ transplant recipients, and the incidence depends on the immunosuppressive treatment and its duration [1] . Visceral leishmaniasis (VL) is a type of parasitosis that is endemic in many developing countries as well as in the Mediterranean region [2] . In recent decades, a high incidence of VL has been reported for immunocompromised adults, including those receiving immunosuppressive therapy, HIV-infected patients, and solid organ transplant recipients [3] [4] [5] . We review the impact of VL on transplant recipients, reporting five cases that occurred in our center (the first of which has been reported elsewhere [6] ).
Case Reports
This case series includes five men who developed VL between 6 and 115 months (mean, 42 months) after transplantation (table 1). All of them received prednisone and azathioprine for immunosuppression, and two patients also received cyclosporine treatment. At admission, they presented with fever and pancytopenia, and organomegaly was detected in all but one patient. Bone marrow biopsy (BMB) was positive in three of four cases in which it was performed, and culture on NovyMcNeal-Nicoll medium was negative for all three patients who underwent this study. The serological test for VL was positive for the three patients for whom it was carried out. Four of the five patients were treated with meglumine antimoniate (Glucantime, Rhône-Poulenc, Antony Cedex, France) at an initial dosage of 20 mg of pentavalent antimony/(kg of body weight ⅐ d).
Patient 1 was admitted to the hospital 18 months after transplantation because of disseminated intravascular coagulation. Leishmanial infection was not suspected. An abscess in the right renal fossa was drained, and despite antibiotic therapy, the patient died. Necropsy disclosed the presence of the intracellular pathogen Leishmania donovani. Patient 2's condition improved when he was treated with meglumine antimoniate for 20 days. Four years later, the patient presented with post-kala-azar cutaneous leishmaniasis and a lesion involving the tongue mucosa. An inflammatory infiltrate composed of lymphocytes, plasma cells, and histiocytes was detected in the nose and tongue, and amastigotes were isolated from the tongue lesion. PCR analysis was positive for Leishmania donovani infantum. The patient was successfully treated with liposomal amphotericin B (AmBisome, Vestar, San Dimas, CA) at a dosage of 1.25 mg/(kg of body weight ⅐ d) for 1 month. Patient 3's condition improved after receiving meglumine antimoniate therapy for 1 month. However, he presented with five recurrences over a 6-month interval, which were treated with a 1-month regimen of meglumine antimoniate at the same dosage (20 NOTE. ALLO ϭ allopurinol; AmB ϭ amphotericin B; BAL ϭ bronchoalveolar lavage; BMB ϭ bone marrow biopsy; Cpfx ϭ ciprofloxacin; HS ϭ hepatosplenomegaly; Ket ϭ ketoconazole; LB ϭ liver biopsy; MA ϭ meglumine antimoniate; Mtz ϭ metronidazole; NNN ϭ Novy-McNeal-Nicoll; Pm ϭ paromomycin; PR ϭ present report; SS ϭ sodium stibogluconate; ϩ ϭ positive; Ϫ ϭ negative; . . . ϭ not done or not specified; 3 ϭ replaced by. * Previous splenectomy. † Cutoff point for serological test for Leishmania in our hospitals is 1/80 [28] . ‡ Post-kala-azar cutaneous leishmaniasis.
ropsy revealed the presence of Streptococcus pneumoniae bronchopneumonia but did not disclose evidence of infection with Leishmania. Patient 5 was treated with meglumine antimoniate and allopurinol (900 mg/d) and died suddenly 14 days later.
Discussion
We present five cases of VL in patients who underwent organ transplantation in our hospital, where 456 kidney, 425 heart, and 353 liver transplantations have been performed. We reviewed the literature and found another 26 cases of VL in 24 kidney transplant recipients [5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , 1 kidney-pancreas transplant recipient [26] , and 1 liver transplant recipient [27] .
Most of the cases occurred in the Mediterranean region and the Middle East. In the other cases, the patients had previously traveled to regions of endemicity [7, 8, 17] or the transplanted organ was considered to be the source of infection [27] . Seventeen (55%) of the 31 cases were diagnosed in Spain.
Most of the patients were men. The mean age of the patients was 43 years (range, 23-63 years). The mean interval between transplantation and disease onset was 32 months (nine cases occurred during the first 6 months, the period of maximum immunosuppression). All but one of the patients [24] presented with fever, and 86% had splenomegaly or hepatosplenomegaly. One patient presented with retroperitoneal lymph node involvement [22] . Cytopenia was observed in all the patients, and 54% had hypergammaglobulinemia. Indirect immunofluorescence disclosed the presence of antibodies to Leishmania in 18 of 22 cases; this elevated diagnostic sensitivity was similar to that found for other patient populations, with the exception of HIV-infected patients for whom the rate was 34% [29] . Since conventional immunosuppression does not alter the humoral response, the detection of antibodies to Leishmania in these cases is useful as a diagnostic tool, as a marker of recurrence, and to identify candidates for transplantation in areas of endemicity.
The interval between the onset of symptoms and the definitive diagnosis ranged between a few days and several months. Delayed diagnoses may have been due to the similarity to other types of infection, negative BMB, drug-induced pancytopenia, or a low degree of suspicion [17, 22] . The diagnosis was based on the detection of amastigotes in BMB specimens from 96% of the patients. Culture on Novy-McNeal-Nicoll medium was positive in 50% of cases.
The treatment of choice for VL is the administration of pentavalent antimonial compounds: meglumine antimoniate and sodium stibogluconate [2] . In the cases reviewed here, antimonials were employed in 28 cases. In three cases, because of the fulminant course of the disease, the patients died before any kind of treatment could be begun ( [5, 7] and case 1).
Recurrence-free cures were achieved in 15 cases (48%). Nine patients (29%) died (table 1); seven deaths (78%) were due to superinfection. In one case, the cause of death was not specified [5] , and patient 5 died without finishing the treatment regimen.
Seven patients (23%) presented with recurrence ( [11, 13, 15, 21, 22, 24] and case 3); two had two recurrences [15, 21] , and one had five (case 3). Recurrence was successfully managed by increasing the drug dosage [13, 22] , adding allopurinol [15, 24] , adding allopurinol and performing splenectomy [21] , or replacing the initial treatment with amphotericin B [15] or paromomycin [11] . In one case, fluconazole was administered as prophylaxis [27] , and patient 3 received treatment with meglumine antimoniate plus liposomal amphotericin B after these two drugs failed when administered separately. Patient 2 developed post-kala-azar cutaneous leishmaniasis 4 years after transplantation and was treated successfully with liposomal amphotericin B. The rate of recurrence is greater among HIVinfected patients [4, 29] , a finding that could be related to the permanent reduction in the production of IL-2 and IFN-␥. Prophylactic administration of antimonials [30] or itraconazole [31] has been found to be effective for HIV-positive patients. This strategy may also be advisable for transplant recipients.
Seven patients (23%) presented with adverse effects secondary to treatment with pentamonials: acute pancreatitis [8, 11, 16, 19, 25] ; palindromic arthropathy [11] ; renal tubular acidosis, bone marrow toxicity, and electrocardiographic changes [27] ; and anasarca and oliguria [23] . The initial agents were replaced by paromomycin [11] , allopurinol plus ketoconazole [16] , ciprofloxacin followed by amphotericin B [27] , and liposomal amphotericin B [25] .
Liposomal amphotericin B is an effective alternative to treatment with pentamonials. Short courses of liposomal amphotericin B (4 mg/[kg of body weight ⅐ d] for 6 days) have been used successfully for treatment of severe or recurrent VL in other groups of patients [32] .
In conclusion, VL is an infectious disease that has seldom been described in solid organ transplant recipients. Nevertheless, it should be included in the differential diagnosis of these patients when they present with fever, pancytopenia, and organomegaly and live in or have traveled to regions of endemicity. The diagnosis is based on BMB. Although the treatment of choice is administration of pentavalent antimony, the high rate of failure and the toxicity associated with these drugs are important reasons for using other agents such as liposomal amphotericin B for treatment and prophylaxis.
